Verastem Inc
F:2VS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Verastem Inc
F:2VS
|
US |
|
Intel Corp
NASDAQ:INTC
|
US |
|
I
|
International Business Machines Corp
DUS:IBM
|
US |
|
M
|
Mitsubishi Heavy Industries Ltd
F:MIH
|
JP |
|
O
|
Oneflow AB
F:L58
|
SE |
|
John Wiley & Sons Inc
NYSE:WLY
|
US |
|
Xcel Energy Inc
NASDAQ:XEL
|
US |
|
Banco Santander SA
MIL:SANT
|
ES |
|
I
|
International Flavors & Fragrances Inc
F:IFF
|
US |
|
Limbach Holdings Inc
F:J4B
|
US |
|
Global Water Resources Inc
NASDAQ:GWRS
|
US |
|
Lifebrandz Ltd
SGX:1D3
|
SG |
|
E
|
Enbridge Inc
NYSE:ENB
|
CA |
|
A
|
Arthur J Gallagher & Co
F:GAH
|
US |
|
S
|
Shiseido Co Ltd
XBER:SHD
|
JP |
|
A
|
Akamai Technologies Inc
SWB:AK3
|
US |
|
C
|
CBRE Group Inc
XMUN:RF6
|
US |
|
S
|
Sandvik AB
XBER:SVKB
|
SE |
|
Sekisui House Ltd
OTC:SKHSF
|
JP |
|
Wipro Ltd
NSE:WIPRO
|
IN |
Verastem Inc
Verastem is a biotechnology company focused on cancer drugs, especially medicines that target tumors driven by the RAS/MAPK signaling pathway. Its main work is to develop, test, and bring to market prescription therapies for hard-to-treat cancers, with a strong emphasis on ovarian cancer and other solid tumors. In simple terms, it is a drug maker, not a hospital or a research tools company. The company sells its treatments through the medical system, so its main customers are oncologists, cancer centers, hospitals, and the pharmacies and payers that support patient access. Verastem makes money mainly from sales of approved drugs, and it can also earn income from collaboration, licensing, or development agreements tied to its drug pipeline. Because it is a biotech company, a big part of its value comes from whether its clinical programs lead to approved medicines that doctors can prescribe. What makes Verastem different is its narrow focus on a specific cancer biology pathway and on combination therapies, rather than on a broad range of medicines. That gives it a specialized role in the oncology market: it tries to find patient groups that may respond better to targeted treatment and then commercialize those therapies through the standard drug distribution and reimbursement system.
Verastem is a biotechnology company focused on cancer drugs, especially medicines that target tumors driven by the RAS/MAPK signaling pathway. Its main work is to develop, test, and bring to market prescription therapies for hard-to-treat cancers, with a strong emphasis on ovarian cancer and other solid tumors. In simple terms, it is a drug maker, not a hospital or a research tools company.
The company sells its treatments through the medical system, so its main customers are oncologists, cancer centers, hospitals, and the pharmacies and payers that support patient access. Verastem makes money mainly from sales of approved drugs, and it can also earn income from collaboration, licensing, or development agreements tied to its drug pipeline. Because it is a biotech company, a big part of its value comes from whether its clinical programs lead to approved medicines that doctors can prescribe.
What makes Verastem different is its narrow focus on a specific cancer biology pathway and on combination therapies, rather than on a broad range of medicines. That gives it a specialized role in the oncology market: it tries to find patient groups that may respond better to targeted treatment and then commercialize those therapies through the standard drug distribution and reimbursement system.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
